



TMC LIFE SCIENCES BERHAD
Company no. 200301021989 (624409-A)
(Incorporated in Malaysia)

**UNAUDITED INTERIM FINANCIAL REPORT
FOR THE FINANCIAL QUARTER ENDED
31 MARCH 2026**

Contact

Level 11, No.11, Jalan Teknologi,
Taman Sains Selangor 1, PJU 5,
Kota Damansara
47810 Petaling Jaya, Selangor D.E.

Tel: +603 6287 1111
Fax: +603 6287 1212

www.tmlife.com

TMC LIFE SCIENCES BERHAD
Company no. 200301021989 (624409-A)
(Incorporated in Malaysia)

**UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
FOR THE FINANCIAL PERIOD ENDED 31 MARCH 2026**

	Individual Quarter		9 months ended	
	Current Year Quarter	Preceding Year Quarter	Current Year To Date	Preceding Year Corresponding Period
	31/03/2026 RM'000	31/03/2025 RM'000	31/03/2026 RM'000	31/03/2025 RM'000
Revenue	89,701	89,872	293,675	252,265
Other operating income	1,335	1,240	4,487	3,194
Inventories and consumables	(31,710)	(30,565)	(106,342)	(83,028)
Staff costs	(28,389)	(30,501)	(86,113)	(88,716)
Other operating expenses	(17,686)	(19,446)	(55,239)	(51,149)
Depreciation and amortisation	(9,424)	(9,058)	(28,172)	(24,906)
Interest income	728	801	2,158	3,461
Finance costs	(1,806)	(2,291)	(5,801)	(7,103)
Profit before taxation	2,749	52	18,653	4,018
Taxation	(991)	(858)	(5,921)	(2,835)
Profit / (Loss) for the financial period, representing total comprehensive income / (loss) (net of tax) for the financial period	1,758	(806)	12,732	1,183
Profit / (Loss) for the financial period, representing total comprehensive income / (loss) (net of tax) for the financial period attributable to:- Owners of the parent	1,758	(806)	12,732	1,183
Profit / (Loss) per ordinary share attributable to the owners of the parent (sen)				
Basic / Diluted	0.10	(0.05)	0.73	0.07

The unaudited condensed consolidated statement of comprehensive income should be read in conjunction with the accompanying explanatory notes attached to the unaudited interim financial statements.

TMC LIFE SCIENCES BERHAD
Company no. 200301021989 (624409-A)
(Incorporated in Malaysia)

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
FOR THE FINANCIAL PERIOD ENDED 31 MARCH 2026

	Attributable to owners of the parent			Total equity RM'000
	Share capital RM'000	Non-distributable	Distributable	
		Share options reserve RM'000	Retained profits RM'000	
Balance at 1 July 2025	625,986	-	227,057	853,043
Profit for the financial period, representing total comprehensive income (net of tax) for the financial period	-	-	12,732	12,732
Transaction with owners				
Dividend paid	-	-	(3,245)	(3,245)
Balance at 31 March 2026	625,986	-	236,544	862,530
Balance at 1 July 2024	625,986	1,316	260,732	888,034
Profit for the financial year, representing total comprehensive income (net of tax) for the financial year	-	-	3,606	3,606
Transactions with owners				
Share options granted under ESOS	-	19	-	19
Transfer within reserve for ESOS forfeited	-	(1,335)	1,335	-
Dividend paid	-	-	(38,616)	(38,616)
Total transactions with owners	-	(1,316)	(37,281)	(38,597)
Balance at 30 June 2025	625,986	-	227,057	853,043

The unaudited condensed consolidated statement of changes in equity should be read in conjunction with the audited financial statements for the financial year ended 30 June 2025 and the accompanying explanatory notes attached to the unaudited interim financial statements.

TMC LIFE SCIENCES BERHAD
Company no. 200301021989 (624409-A)
(Incorporated in Malaysia)

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AS AT 31 MARCH 2026

	As At 31/03/2026 Unaudited RM'000	As At 30/06/2025 Audited RM'000
Non-current assets		
Property, plant and equipment	715,103	725,778
Intangible assets	196,836	201,192
Investment property	1,995	2,039
Deferred tax assets	701	700
Total non-current assets	914,635	929,709
Current assets		
Inventories	18,638	15,908
Trade and other receivables	57,869	65,600
Tax recoverable	744	11,409
Cash and bank balances	118,116	109,564
Total current assets	195,367	202,481
TOTAL ASSETS	1,110,002	1,132,190
Current liabilities		
Contract liabilities	553	519
Trade and other payables	58,540	69,286
Borrowings	45,109	38,047
Lease liabilities	1,827	1,901
Income tax payable	1,085	559
Total current liabilities	107,114	110,312
NET CURRENT ASSETS	88,253	92,169
Non-current liabilities		
Contract liabilities	385	357
Borrowings	107,757	141,426
Lease liabilities	1,460	1,598
Provision	663	739
Deferred tax liabilities	30,093	24,715
Total non-current liabilities	140,358	168,835
TOTAL LIABILITIES	247,472	279,147
NET ASSETS	862,530	853,043
Represented by:		
Equity attributable to owners of the parent		
Share capital	625,986	625,986
Retained profits	236,544	227,057
TOTAL EQUITY	862,530	853,043
Net assets per share (RM)	0.50	0.49

The unaudited condensed consolidated statement of financial position should be read in conjunction with the audited financial statements for the financial year ended 30 June 2025 and the accompanying explanatory notes attached to the unaudited interim financial statements.

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE FINANCIAL PERIOD ENDED 31 MARCH 2026

	Current Year To Date 31/03/2026 RM'000	Preceding Year Corresponding Period 31/03/2025 RM'000
Cash flows from operating activities		
Profit before tax	18,653	4,018
Adjustments for :-		
Non-cash items	28,948	25,683
Interest expense	5,801	7,103
Interest income	(2,158)	(3,461)
Operating profit before changes in working capital	<u>51,244</u>	<u>33,343</u>
Changes in working capital		
Net change in current assets	4,217	(18,245)
Net change in trade and other payables and contract liabilities	(10,761)	5,273
Cash generated from operations	<u>44,700</u>	<u>20,371</u>
Interest paid	(5,629)	(6,951)
Net income tax refunded / (paid)	<u>10,648</u>	<u>(1,586)</u>
Net cash flows generated from operating activities	<u>49,719</u>	<u>11,834</u>
Cash flows from investing activities		
Acquisition of property, plant and equipment	(10,756)	(30,487)
Acquisition of intangible assets	(712)	(449)
Proceeds from disposal of property, plant and equipment	9	3
Withdrawal of deposits placed with:-		
- financial institutions with original maturity of more than three (3) months	28,589	32,562
- deposits pledged	90	210
Interest received	2,158	3,461
Net cash flows generated from investing activities	<u>19,378</u>	<u>5,300</u>
Cash flows used in financing activities		
Dividend paid	(3,245)	(38,616)
Payment of lease liabilities	(1,850)	(1,822)
Repayment of term loans	(26,331)	(15,075)
Repayment of hire purchase	(441)	(662)
Net cash flows used in financing activities	<u>(31,867)</u>	<u>(56,175)</u>
Net increase/(decrease) in cash & cash equivalents	<u>37,230</u>	<u>(39,041)</u>
Cash & cash equivalents at beginning of the financial period	<u>60,822</u>	<u>107,511</u>
Cash & cash equivalents at end of the financial period	<u>98,052</u>	<u>68,470</u>
Cash & cash equivalents at end of the financial period		
Cash at banks and on hand	58,696	49,642
Deposits with licenced banks	59,420	67,117
	<u>118,116</u>	<u>116,759</u>
Less: Deposits with licenced banks (for more than 3 months)	(16,048)	(44,299)
Deposit pledged to a licenced bank	(1,556)	(1,530)
Cash restricted in use	(2,460)	(2,460)
	<u>98,052</u>	<u>68,470</u>

The unaudited condensed consolidated statement of cash flows should be read in conjunction with the accompanying explanatory notes attached to the unaudited interim financial statements.

TMC LIFE SCIENCES BERHAD
Company no. 200301021989 (624409-A)
(Incorporated in Malaysia)

**NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT
FOR THE FINANCIAL PERIOD ENDED 31 MARCH 2026**

**A EXPLANATORY NOTES PURSUANT TO MALAYSIAN FINANCIAL REPORTING
STANDARDS (“MFRS”)**

A1 BASIS OF PREPARATION

The interim financial report is unaudited and has been prepared in compliance with Malaysian Financial Reporting Standards ("MFRS") 134 - Interim Financial Reporting and paragraph 9.22 of the Main Market Listing Requirements of Bursa Malaysia Securities Berhad.

The interim financial report should be read in conjunction with the audited financial statements of TMC Life Sciences Berhad and its subsidiaries ("the Group") for the financial year ended 30 June 2025. The explanatory notes attached to the unaudited interim financial statements provide an explanation of events and transactions that are significant for understanding the changes in the financial position of the Group since the financial year ended 30 June 2025, and changes in financial performance since the preceeding year corresponding period.

The accounting policies and methods of computations used in the preparation of the unaudited interim financial statements are consistent with those adopted in the audited financial statements for the financial year ended 30 June 2025, except for the adoption of the new, revised and amendments to MFRS and IC Interpretations effective as of 1 January 2025 as issued by the Malaysian Accounting Standards Board, which does not have any significant impact on the unaudited interim financial statements of the Group.

A2 SEASONALITY OR CYCLICALITY OF OPERATIONS

The Group's business is typically impacted during festive and holiday periods when a decrease in patient load is anticipated.

A3 UNUSUAL ITEMS AFFECTING ASSETS, LIABILITIES, EQUITY, NET INCOME OR CASH FLOWS

There were no material items or events that arose, which affected assets, liabilities, equity, net income or cash flows that are unusual by reasons of their nature, size or incidence.

A4 CHANGE IN ACCOUNTING ESTIMATES

There were no material changes in the nature and amount of estimates reported that have a material effect in the current financial quarter under review.

A5 ISSUANCE AND REPAYMENT OF DEBT AND EQUITY SECURITIES

There were no issuance, cancellation, repurchases, resale and repayment of debt and equity securities in the current financial quarter under review.

A6 DIVIDEND PAID

During the financial period ended 31 March 2026, the Company paid a final single tier dividend of 0.1863 sen per ordinary share on 1,741,882,393 ordinary shares, amounting to RM3,245,111 in respect of the financial year ended 30 June 2025.

A7 SEGMENTAL INFORMATION

The Group operates mainly in Malaysia and is involved in the healthcare sector which includes providing specialist healthcare services in its multi disciplinary tertiary hospital and fertility centres.

A8 MATERIAL EVENT SUBSEQUENT TO THE END OF THE INTERIM REPORTING PERIOD

There was no material event subsequent to 31 March 2026 and up to the date of this report that would likely affect substantially the results of the operations of the Group.

A9 CHANGES IN THE COMPOSITION OF THE GROUP

There were no changes in the composition of the Group during the current quarter under review.

A10 CONTINGENT LIABILITIES OR CONTINGENT ASSETS

Financial guarantees	31/03/2026	30/06/2025
	RM'000	RM'000
<u>Unsecured</u>		
Corporate guarantees given to licensed bank for banking facility granted to wholly-owned subsidiaries	152,866	179,473
Letter of guarantee given to suppliers	3,948	9,225
	<u>156,814</u>	<u>188,698</u>

A11 CAPITAL COMMITMENTS

The amount of commitments for capital expenditure is as follows:

	31/03/2026	30/06/2025
	RM'000	RM'000
Approved and contracted for	<u>40,685</u>	<u>29,581</u>

A12 SIGNIFICANT RELATED PARTY TRANSACTIONS

There were no significant related party transactions during the quarter under review.

**NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT
FOR THE FINANCIAL PERIOD ENDED 31 MARCH 2026**

B ADDITIONAL INFORMATION REQUIRED BY BURSA MALAYSIA SECURITIES BERHAD (“BURSA SECURITIES”)

B1 REVIEW OF THE PERFORMANCE OF THE GROUP

Analysis of performance

Review of results for the financial quarter (3 months ended 31 March 2026 versus 3 months ended 31 March 2025)

	3 months ended	
	31/03/2026	31/03/2025
	RM'000	RM'000
Revenue	89,701	89,872
Profit before taxation	2,749	52

For the quarter ended 31 March 2026, the Group recorded revenue of RM89.7 million and profit before taxation of RM2.7 million, an improvement in profit before taxation compared to the previous corresponding quarter. This performance was due to continued cost optimisation initiatives.

Review of results for the financial period (9 months ended 31 March 2026 versus 9 months ended 31 March 2025)

	9 months ended	
	31/03/2026	31/03/2025
	RM'000	RM'000
Revenue	293,675	252,265
Profit before taxation	18,653	4,018

For the financial period ended 31 March 2026, the Group reported a 16 % increase in revenue to RM293.7 million and an improvement in profit before taxation of RM18.7 million, compared to the same period ended 31 March 2025. This performance was driven by the rebound in hospital revenue and continued cost optimisation initiatives.

Material factors affecting the earnings and / or revenue of the Group

The material factors that affect the earnings and / or revenue of the Group are the successful recruitment of healthcare professionals in our facilities, additional bed capacity and additional services offered by the Group, higher case intensity handled, and continuous marketing effort to boost local and international branding.

**B2 MATERIAL CHANGE IN PROFIT BEFORE TAX AS COMPARED WITH IMMEDIATE PRECEDING QUARTER
(3 months ended 31 March 2026 versus 3 months ended 31 December 2025)**

	3 months ended	
	31/03/2026	31/12/2025
	RM'000	RM'000
Revenue	89,701	103,497
Profit before taxation	2,749	9,336

Compared to the immediate preceding quarter ended 31 December 2025, revenue and profit before taxation declined by 13% and 71%, respectively. The decrease in profit before taxation was attributable to a lower patient load during the festive and prolonged public holiday periods.

B3 PROSPECTS FOR THE FINANCIAL YEAR ENDING 30 JUNE 2026

The private healthcare landscape continues to be shaped by evolving payor dynamics, with insurers and corporate customers placing increased emphasis on affordability, efficiency and value-based outcomes. In response, the Group is proactively executing its value-based care strategy. This approach focuses on delivering high-quality clinical outcomes in a financially sustainable manner, ensuring we remain a preferred partner for insurers while maintaining our commitment to excellence in patient care.

The impact of global geopolitical situation may cause supply chain disruptions and inflationary pressures. However, the Group has strengthened its operational resilience through cost optimisation and the diversification of procurement sourcing in preparation of any potentiality.

The Group's growth trajectory remains robust, underpinned by the increased capacity at Thomson Hospital Kota Damansara and the strategic expansion of key specialties. The Group is also actively diversifying its revenue base by strengthening its presence in the corporate segment, broadening its international patient mix, and scaling its fertility business to capture regional demand, thereby sustaining long-term shareholder value.

B4 VARIANCE ON PROFIT FORECAST/PROFIT GUARANTEE

There is no profit forecast or profit guarantee for the financial period ended 31 March 2026

B5 TAXATION

	Individual quarter		9 months ended	
	31/03/2026	31/03/2025	31/03/2026	31/03/2025
	RM'000	RM'000	RM'000	RM'000
In respect of current quarter / financial period				
Current tax expense	56	236	542	1,530
Deferred tax expense	935	622	5,379	1,305
	<u>991</u>	<u>858</u>	<u>5,921</u>	<u>2,835</u>

Tax provision during the current quarter refers to recognition of tax expense for profit making subsidiaries.

B6 STATUS OF CORPORATE PROPOSAL

There are no corporate proposals announced but not completed as at 13 May 2026, being the latest practicable date which shall not be earlier than 7 days from the date of this quarterly report.

B7 BORROWINGS

The Group's borrowings are as follows:-

	Long Term	Short Term	Total
	RM'000	RM'000	RM'000
As at 31 March 2026			
Secured - Denominated in Ringgit Malaysia	<u>107,757</u>	<u>45,109</u>	<u>152,866</u>
As at 30 June 2025			
Secured - Denominated in Ringgit Malaysia	<u>141,426</u>	<u>38,047</u>	<u>179,473</u>

Included in the Group's borrowings is industrial hire purchase of NIL as at the reporting date (30 June 2025: RM442,000).

B8 MATERIAL LITIGATION

There was no material litigation as at the date of this report.

B9 DIVIDENDS

The Board does not recommend any dividend for the current quarter under review (previous year corresponding period ended 31 March 2025: NIL)

B10 EARNINGS PER SHARE (EPS)

	Individual quarter		9 months ended	
	31/03/2026	31/03/2025	31/03/2026	31/03/2025
Basic / Diluted EPS				
Net profit / (loss) attributable to owners of the parent (RM'000)	<u>1,758</u>	<u>(806)</u>	<u>12,732</u>	<u>1,183</u>
Weighted average number of ordinary shares in issue ('000)	<u>1,741,882</u>	<u>1,741,882</u>	<u>1,741,882</u>	<u>1,741,882</u>
EPS (sen)				
- Basic / Diluted	<u>0.10</u>	<u>(0.05)</u>	<u>0.73</u>	<u>0.07</u>

B11 AUDITORS' REPORT ON PRECEDING ANNUAL FINANCIAL STATEMENTS

The audit report of the preceding annual financial statements was unqualified.

B12 NOTE TO STATEMENT OF COMPREHENSIVE INCOME

	Individual quarter		9 months ended	
	31/03/2026	31/03/2025	31/03/2026	31/03/2025
	RM'000	RM'000	RM'000	RM'000
Interest income	728	801	2,158	3,461
Interest expense	(1,804)	(2,288)	(5,795)	(7,092)
Unwinding of discount on provision for restoration	(2)	(3)	(6)	(11)
Depreciation of property, plant and equipment,				
investment property and right-of-use assets	(7,695)	(7,355)	(22,997)	(20,742)
Amortisation of intangible assets	(1,729)	(1,703)	(5,175)	(4,164)
Impairment loss on receivables	(299)	(210)	(719)	(630)
Fair value charges on share options granted under ESOS	-	(5)	-	(15)
Property, plant and equipment written off	(14)	(1)	(30)	(13)
Gain on disposal of property, plant and equipment	6	2	9	2
Gain on provision of restoration	19	-	19	-
Gain on derecognition of lease liability	-	1	8	1
Inventories written off	<u>(14)</u>	<u>(14)</u>	<u>(63)</u>	<u>(122)</u>

B13 DERIVATIVE FINANCIAL INSTRUMENTS

The Group did not enter into any derivative financial instruments which were outstanding as at 31 March 2026 and 30 June 2025.

B14 AUTHORISED FOR ISSUE

The unaudited condensed consolidated interim financial statements were authorised for issue by the Board of Directors in accordance with a resolution of the Directors on 20 May 2026.